Targeting therapy using the drugs selected by genetic detection is to block specific gene target and signaling pathway in tumor cells. The therapy can kill the tumor cells and does not affect normal cells, and has good curative effect and less side effects, so it is considered to be a treatment option of combined therapy for oral and maxillofacial-head and neck cancer. Targeting therapy combined by radiation therapy improves radiosensitivity. For advanced patients with tumor recurrence, or with distant metastasis, who can't tolerate with concurrent radiation and chemotherapy, targeted therapy can be used alone. Targeting therapy can decline risks of recurrence or worsening, and has the very big advantage in clinical application, and is becoming one of the indispensable important means of the combined therapy in the patients with oral and maxillofacial-head and neck cancer.
. Targeted Therapy: the Treatment Option of Combined Therapy for Oral-maxillofacial-head and Neck Cancer[J]. Journal of Oral and Maxillofacial Surgery, 2017, 27(4): 229-.
王中和. 口腔颌面-头颈肿瘤放射治疗学[M]. 上海: 上海世界图书出版公司, 2013.
Prasasya RD, Tian D, Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies[J]. Semin Cancer Biol, 2011, 21(3):200-206.
Freidlin B, McShane LM, Polley MY, et al. Randomized phase II trial designs with biomarkers[J]. J Clin Oncol, 2012, 30(26): 3304-3309.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6):567-578.
Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck--An update[J]. Oral Oncol, 2015, 51(7):652-661.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival[J]. Lancet Oncol, 2010, 11(1):21-28.
Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5):343-349.
Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma(NPC): preliminary report[J]. J Clin Oncol, 2010, 28(15):5577-5577.
Cohen EE, Haraf DJ, Kunnavakkam R, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer[J]. J Clin Oncol, 2010, 28(20):3336-3343.
Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):696-702.
Croci DO, Cerliani JP, Dalotto-Moreno T, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors[J]. Cell, 2014, 156(4):744-758.
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298-307.
Almangush A, Heikkinen I, Makitie AA, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis[J]. Br J Cancer, 2017, 117(6):856-866.
Kuwahara Y, Mori M, Kitahara S, et al. Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors[J]. Cancer Med, 2014, 3(2):310-321.
Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7): 1253-1256.
Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008, 30(2):262-266.
Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer[J]. J Clin Oncol, 2011, 29(9):1140-1145
Li L, Liu RY, Huang JL, et al. Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma[J]. Int J Cancer, 2006, 118(8):2064-2071.
Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study[J]. Oral Oncol, 2003, 39(7):724-727.
Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma[J]. Br J Oral Maxillofac Surg, 2011, 49(7):510-515.
Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC[J]. Ann Oncol, 2012, 23(6):1562-1570.
Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies[J]. Cancer Biol Ther, 2013, 14(4):304-314.
Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer[J]. Cancer Res, 2013, 73(11):3381-3392.
Calzone L, Kuperstein I, Cohen D, et al. Biological network modelling and precision medicine in oncology[J]. Bull Cancer, 2014, 101(Suppl 1):S18-S21.
Papadatos-Pastos D, De Miguel Luken MJ, Yap TA. Combining targeted therapeutics in the era of precision medicine[J]. Br J Cancer, 2015, 112(1):1-3.
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies[J]. CA Cancer J Clin, 2013, 63(4):249-279.
Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality[J]. Ann Oncol, 2014, 25(12):2304-2313.
Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations[J]. Semin Oncol, 2015, 42(3):363-377.
Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy[J]. Eur J Immunol, 2015, 45(7):1892-1905.